Gamida Cell initiated at Needham

Gamida Cell initiated with a Buy at Needham. Needham analyst Chad Messer initiated Gamida Cell with a Buy rating and a price target of $23. The analyst notes that nearly half of the U.S. patients who are eligible for stem cell transplants never receive one because they cannot find a suitable bone marrow donor. Messer states that Gamida Cell’s NiCord system addresses the “shortcomings of cord blood transplantation by using its proprietary technology to maintain cell ‘stemness’ during expansion in culture”. The analyst is therefore positive on the company’s “promise of greatly increasing the number of transplant-eligible patients who can find a potentially lifesaving donor match.”
https://thefly.com/landingPageNews.php?id=2827623